for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Clovis Oncology Inc

CLVS.OQ

Latest Trade

8.66USD

Change

0.90(+11.60%)

Volume

2,259,317

Today's Range

7.71

 - 

8.72

52 Week Range

2.94

 - 

32.03

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

D. E. Shaw & Co. Reports Passive Stake Of 5.4% In Clovis Oncology

Nov 15 (Reuters) - :D. E. SHAW & CO., L.P. REPORTS PASSIVE STAKE OF 5.4% IN CLOVIS ONCOLOGY, INC AS OF NOVEMBER 5, 2019 - SEC FILING.

Clovis Oncology Reports Q3 Global Net Product Revenue $37.6 Million

Nov 7 (Reuters) - Clovis Oncology Inc <CLVS.O>::QTRLY NET PRODUCT REVENUE INCREASED 14% SEQUENTIALLY IN Q3 2019.QTRLY NET PRODUCT REVENUE $37.6 MILLION VERSUS $22.8 MILLION.Q3 REVENUE VIEW $35.8 MILLION -- REFINITIV IBES DATA.NOW EXPECTS GLOBAL NET PRODUCT REVENUE TO BE IN RANGE OF $141 MILLION TO $147 MILLION FOR FULL YEAR 2019.

Kenneth Griffin Reports 7.0% Passive Stake In Clovis Oncology Inc

Aug 16 (Reuters) - Clovis Oncology Inc <CLVS.O>::KENNETH GRIFFIN REPORTS 7.0% PASSIVE STAKE IN CLOVIS ONCOLOGY INC AS OF AUGUST 9 - SEC FILING.

Clovis Oncology Announces Pricing Of $250 Mln Of Convertible Senior Notes

Aug 8 (Reuters) - Clovis Oncology Inc <CLVS.O>::CLOVIS ONCOLOGY ANNOUNCES PRICING OF $250 MILLION OF CONVERTIBLE SENIOR NOTES.CLOVIS ONCOLOGY INC - PRICING OF $250 MILLION AGGREGATE PRINCIPAL AMOUNT OF ITS 4.50% CONVERTIBLE SENIOR NOTES DUE 2024.

Clovis Oncology To Offer $225 Million Of Convertible Senior Notes

Aug 7 (Reuters) - Clovis Oncology Inc <CLVS.O>::CLOVIS ONCOLOGY TO OFFER $225 MILLION OF CONVERTIBLE SENIOR NOTES.CLOVIS ONCOLOGY INC - INTENDS TO OFFER $225 MILLION AGGREGATE PRINCIPAL AMOUNT OF ITS CONVERTIBLE SENIOR NOTES DUE 2024.CLOVIS ONCOLOGY - ALSO EXPECTS TO GRANT INITIAL PURCHASERS A 13-DAY OPTION TO PURCHASE UP TO $33.75 MILLION AGGREGATE PRINCIPAL AMOUNT OF ADDITIONAL NOTES.

Clovis Oncology Reports Q2 Loss Per Share $2.27

Aug 1 (Reuters) - Clovis Oncology Inc <CLVS.O>::CLOVIS ONCOLOGY ANNOUNCES SECOND QUARTER 2019 OPERATING RESULTS.Q2 LOSS PER SHARE $2.27.Q2 EARNINGS PER SHARE ESTIMATE $-1.71 -- REFINITIV IBES DATA.$33.0M IN RUBRACA(®) (RUCAPARIB) NET PRODUCT REVENUE FOR Q2 2019 COMPARED TO $23.8M FOR Q2 2018.GLOBAL NET PRODUCT REVENUE GUIDANCE OF $137 MILLION TO $147 MILLION PROVIDED FOR FULL YEAR 2019.SUPPLEMENTAL NDA FOR RUBRACA IN BRCA-MUTANT ADVANCED PROSTATE CANCER ON TRACK FOR Q4 2019.CLOVIS HAD $315.9 MILLION IN CASH, CASH EQUIVALENTS AND AVAILABLE-FOR-SALE SECURITIES AS OF JUNE 30, 2019.

Clovis Oncology Says On June 14, Co, Antipodean Domestic Partners Entered Into An Agreement

June 17 (Reuters) - Clovis Oncology Inc <CLVS.O>::CLOVIS ONCOLOGY INC - ON JUNE 14, CO, ANTIPODEAN DOMESTIC PARTNERS ENTERED INTO AN AGREEMENT.CLOVIS ONCOLOGY INC - AGREEMENT TO SETTLE LAWSUIT FILED BY ANTIPODEAN AGAINST CO, CERTAIN OF ITS OFFICERS AND DIRECTORS.CLOVIS ONCOLOGY INC - CO WILL PAY TO ANTIPODEAN $4 MILLION IN CASH AND $21 MILLION IN SHARES OF STOCK OF COMPANY.CLOVIS ONCOLOGY INC - ANTIPODEAN WILL DISMISS PENDING LAWSUIT AND RELEASE CO, ITS OFFICERS AND DIRECTORS AND UNDERWRITERS FROM ANY POTENTIAL LIABILITY.CLOVIS ONCOLOGY INC - ANTIPODEAN HAS INFORMED CO THAT IT MAY ESTABLISH A HEDGING POSITION IN RESPECT OF SETTLEMENT SHARES.

Clovis Oncology Names Ginger Graham As Board Chair

June 6 (Reuters) - Clovis Oncology Inc <CLVS.O>::CLOVIS ONCOLOGY NAMES GINGER L. GRAHAM AS NEW BOARD OF DIRECTORS CHAIR.CLOVIS ONCOLOGY INC - M. JAMES BARRETT, CHAIR SINCE INCEPTION, RETIRES FROM BOARD OF DIRECTORS.CLOVIS ONCOLOGY INC - M. JAMES BARRETT RETIRES FROM BOARD OF DIRECTORS.

Clovis Oncology Says Expanded Rubraca Data From Ariel3 And Triton2 Trials In Ovarian And Prostate Cancers To Be Presented At 2019 ASCO Annual Meeting

June 1 (Reuters) - Clovis Oncology Inc <CLVS.O>::EXPANDED RUBRACA® (RUCAPARIB) DATA FROM CLOVIS ONCOLOGY’S ARIEL3 AND TRITON2 TRIALS IN OVARIAN AND PROSTATE CANCERS TO BE PRESENTED AT 2019 ASCO ANNUAL MEETING.CLOVIS ONCOLOGY INC - UPDATED SAFETY PROFILE GENERATED IN ANALYSIS IS CONSISTENT WITH PREVIOUSLY-REPORTED PRIMARY EFFICACY DATA ANALYSIS.CLOVIS ONCOLOGY - DATA POSITIVELY REINFORCE CURRENT CLINICAL UTILIZATION & UNDERSTANDING OF RUCAPARIB AS MAINTENANCE TREATMENT FOR WOMEN WITH ADVANCED OVARIAN CANCER.

Clovis Oncology Reports Q1 Loss Per Share $1.63

May 7 (Reuters) - Clovis Oncology Inc <CLVS.O>::CLOVIS ONCOLOGY ANNOUNCES FIRST QUARTER 2019 OPERATING RESULTS.Q1 LOSS PER SHARE $1.63.Q1 EARNINGS PER SHARE ESTIMATE $-1.74 -- REFINITIV IBES DATA.33.1M IN RUBRACA (RUCAPARIB) GLOBAL SALES FOR Q1 OF 2018.TARGETING LATE 2019 FOR SUPPLEMENTAL NDA FILING FOR BRCA-MUTANT ADVANCED PROSTATE CANCER.$406.8M IN CASH, CASH EQUIVALENTS AND AVAILABLE FOR SALE SECURITIES AT MARCH 31, 2019.CLOVIS-SPONSORED COMBINATION STUDIES OF LUCITANIB WITH RUCAPARIB AND BRISTOL-MYERS SQUIBB'S OPDIVO EXPECTED TO BEGIN IN MID-2019.Q1 REVENUE VIEW $32.2 MILLION -- REFINITIV IBES DATA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up